RESUMEN
The present study investigated the in vitro metabolic capacity of 28 fungal strains isolated from post-mortem material towards five model drugs: amitriptyline, metoprolol, mirtazapine, promethazine, and zolpidem. Each fungal strain was incubated at 25 °C for up to 120 h with each of the five models drugs. Cunninghamella elegans was used as positive control. Aliquots of the incubation mixture were centrifuged and 50 µL of the supernatants were diluted and directly analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) with product ion scanning. The remaining mixture was analyzed by full scan gas chromatography-mass spectrometry (GC-MS) after liquid-liquid extraction and acetylation. The metabolic activity was evaluated through the total number of detected metabolites (NDM) produced in each model and fungal strains and the percentage of parent drug remaining (%RPD) after up to five days of incubation. All the tested fungal strains were capable of forming mammalian phase I metabolites. Fungi from the normal fungal flora of the human body such as Candida sp., Geotrichum candidum, and Trichosporon asahii) formed up to seven metabolites at %RPD values greater than 52% but no new fungal metabolites (NFM). In contrast, some airborne fungal strains like Bjerkandera adusta, Chaetomium sp, Coriolopsis sp., Fusarium solani and Mucor plumbeus showed NDM values exceeding those of the positive control, complete metabolism of the parent drug in some models and formation of NFM. NFM (numbers in brackets) were detected in four of the five model drugs: amitriptyline (18), metoprolol (4), mirtazapine (8), and zolpidem (2). The latter NFM are potential candidates for marker substances indicating post-mortem fungal metabolism.
Asunto(s)
Amitriptilina/metabolismo , Cadáver , Hongos/metabolismo , Metoprolol/metabolismo , Mianserina/análogos & derivados , Prometazina/metabolismo , Piridinas/metabolismo , Biotransformación , Hongos/aislamiento & purificación , Humanos , Mianserina/metabolismo , Mirtazapina , ZolpidemRESUMEN
AIM: To investigate the influence of gestational diabetes mellitus (GDM) on the kinetic disposition and transplacental and amniotic fluid distribution of metoprolol and its metabolites O-desmethylmetoproloic acid and α-hydroxymetoprolol stereoisomers in hypertensive parturients receiving a single dose of the racemic drug. METHODS: The study was conducted on hypertensive parturients with well-controlled GDM (n = 11) and non-diabetic hypertensive parturients (n = 24), all receiving a single 100 mg oral dose of racemic metoprolol tartrate before delivery. Serial maternal blood samples (0-24 h) and umbilical blood and amniotic fluid samples were collected for the quantitation of metoprolol and its metabolite stereoisomers using LC-MS/MS or fluorescence detection. RESULTS: The kinetic disposition of metoprolol and its metabolites was stereoselective in the diabetic and control groups. Well-controlled GDM prolonged tmax for both enantiomers of metoprolol (1.5 vs. 2.5 h R-(+)-MET; 1.5 vs. 2.75 h S-(-)-MET) and O-desmethylmetoproloic acid (2.0 vs. 3.5 h R-(+)-AOMD; 2.0 vs. 3.0 h S-(-)-OAMD), and for the four stereoisomers of α-hydroxymetoprolol (2.0 vs. 3.0 h for 1'S,2R-, 1'R,2R- and 1'R,2S-OHM; 2.0 vs. 3.5 h for 1'S,2S-OHM) and reduced the transplacental distribution of 1'S,2S-, 1'R,2R-, and 1'R,2S-OHM by approximately 20%. CONCLUSIONS: The kinetic disposition of metoprolol was enantioselective, with plasma accumulation of the S-(-)-MET eutomer. Well-controlled GDM prolonged the tmax of metoprolol and O-desmethylmetoproloic acid enantiomers and the α-hydroxymetoprolol stereoisomers and reduced by about 20% the transplacental distribution of 1'S,2S-, 1'R,2R-, and 1'R,2S-OHM. Thus, well-controlled GDM did not change the activity of CYP2D6 and CYP3A involved in metoprolol metabolism.
Asunto(s)
Antihipertensivos/sangre , Diabetes Gestacional/metabolismo , Hipertensión/tratamiento farmacológico , Metoprolol/sangre , Placenta/metabolismo , Adulto , Antihipertensivos/química , Antihipertensivos/metabolismo , Antihipertensivos/uso terapéutico , Diabetes Gestacional/sangre , Diabetes Gestacional/tratamiento farmacológico , Femenino , Sangre Fetal/química , Humanos , Hipertensión/sangre , Hipertensión/complicaciones , Hipertensión/metabolismo , Recién Nacido , Metoprolol/química , Metoprolol/metabolismo , Metoprolol/uso terapéutico , Parto , Embarazo , Estereoisomerismo , Distribución TisularRESUMEN
OBJECTIVES: The purpose of this study was to phenotype the CYP2D6 in elderly with heart disease classified as extensive metabolizer or poor metabolizers (PM) of metoprolol, develop and validate the method of analysis of metoprolol tartrate and its metabolite in urine using HPLC, and identify potential correlations between anthropometric factors with metabolic ratios of metoprolol/α-OH metoprolol in urine. METHODS: The sample was composed of 130 elderly individuals with a previously identified type of heart condition, with normal renal and hepatic functions. The urine of all the patients were collected 0-8 h after the administration of a pill of 100 mg of metoprolol to determine concentrations of metoprolol and α-hydroxymetoprolol. Those patients presenting a metabolic ratio greater than 12.6 were phenotyped as PM. KEY FINDINGS: The median age of patients was 71.0 years, with a minimum of 60 and maximum of 93 years old. Three patients (2.3%) were phenotyped as PM of metoprolol different from the rate (7-10%) of PM existing in the Caucasian population. CONCLUSIONS: Most of the studied individuals were women, and the proportion of elderly with heart disease classified as PM was smaller than what is usually found among Caucasian populations.
Asunto(s)
Antagonistas de Receptores Adrenérgicos beta 1/metabolismo , Cromatografía Líquida de Alta Presión/métodos , Citocromo P-450 CYP2D6/metabolismo , Cardiopatías , Metoprolol/metabolismo , Fenotipo , Polimorfismo Genético , Antagonistas de Receptores Adrenérgicos beta 1/farmacocinética , Antagonistas de Receptores Adrenérgicos beta 1/orina , Anciano , Anciano de 80 o más Años , Antropometría , Población Negra/genética , Brasil , Citocromo P-450 CYP2D6/genética , Femenino , Cardiopatías/tratamiento farmacológico , Cardiopatías/etnología , Cardiopatías/orina , Humanos , Inactivación Metabólica , Masculino , Metoprolol/análogos & derivados , Metoprolol/farmacocinética , Metoprolol/orina , Persona de Mediana Edad , Oxidación-Reducción , Urinálisis , Población Blanca/genéticaRESUMEN
Metoprolol is a beta-blocker and its racemic mixture is used for the treatment of hypertension. In the present study we investigated the influence of CYP2D and CYP3A on the stereoselective metabolism of metoprolol in rats. Male Wistar rats (n = 6 per group) received racemic metoprolol (15 mg/kg) orally, with or without pretreatment with the CYP inhibitor ketoconazole (50 mg/kg), cimetidine (150 mg/kg), or quinidine (80 mg/kg). Blood samples were collected up to 48 h after metoprolol administration. The plasma concentrations of the stereoisomers of metoprolol, O-demethylmetoprolol (ODM), alpha-hydroxymetoprolol (OHM) (Chiralpak AD column), and metoprolol acidic metabolite (AODM) (Chiralcel OD-R column) were determined by HPLC using fluorescence detection (lambda(exc) = 229 nm; lambda(em) = 298 nm). CYP3A inhibition by ketoconazole reduced the plasma concentrations of ODM and AODM and favored the formation of OHM. CYP2D and CYP3A inhibition by cimetidine reduced the plasma concentrations of OHM and AODM and favored the formation of ODM. The inhibition of CYP2D by quinidine reduced the plasma concentrations of OHM and favored the formation of ODM. In conclusion, the results suggest that CYP3A is involved in the formation of ODM and CYP2D is involved in the formation of AODM.
Asunto(s)
Cimetidina/farmacología , Cetoconazol/farmacología , Metoprolol/metabolismo , Metoprolol/farmacocinética , Quinidina/farmacología , Antagonistas Adrenérgicos beta/sangre , Antagonistas Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/farmacocinética , Animales , Área Bajo la Curva , Cromatografía Líquida de Alta Presión , Inhibidores del Citocromo P-450 CYP3A , Interacciones Farmacológicas , Inhibidores Enzimáticos/farmacología , Ayuno , Concentración de Iones de Hidrógeno , Masculino , Tasa de Depuración Metabólica , Metoprolol/antagonistas & inhibidores , Metoprolol/sangre , Metoprolol/química , Estructura Molecular , Ratas , Ratas Wistar , Espectrometría de Fluorescencia , EstereoisomerismoRESUMEN
We investigated the stereoselective kinetic disposition and metabolism of metoprolol (MET) in rats. The racemic MET (15 mg/kg) was given by oral gavage and blood samples were collected from 0 to 10h (n=6 at each time point). The enantiomeric concentrations of MET and its metabolites alpha-hydroxymetoprolol (alpha-OHM) and O-demethylmetoprolol (ODM) were determined by HPLC using a Chiralpak AD chiral column and fluorescence detection. The pharmacokinetic parameters of unchanged MET and the formation of ODM did not show to be stereoselective. In contrast, the AUC (ng h/mL) of alpha-hydroxymetoprolol isomers were higher to I'R [638.2(525.2-706.2) for 1'R2R and 659.6(580.4-698.1) for 1'R,2S, mean, (95%CI)] than to I'S products [58.3(47.4-66.1) for 1'S,2R and 57.1(44.7-67.9) for 1'S,2S, mean, (95%CI)]. We conclude that the kinetic disposition of unchanged MET and the formation of ODM are not enantioselective in rats but the metabolism of alpha-OHM yields predominantly the 1'R-product.
Asunto(s)
Antagonistas Adrenérgicos beta/sangre , Cromatografía Líquida de Alta Presión/métodos , Metoprolol/sangre , Antagonistas Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/farmacocinética , Animales , Área Bajo la Curva , Calibración , Dicroismo Circular , Semivida , Masculino , Metoprolol/análogos & derivados , Metoprolol/química , Metoprolol/metabolismo , Metoprolol/farmacocinética , Ratas , Ratas Wistar , Reproducibilidad de los Resultados , EstereoisomerismoRESUMEN
We have shown that the stimulation of beta-adrenoceptors is an important step in venom production in the Bothrops jararaca venom gland. In the present study, the pharmacological profile of the beta-adrenoceptor present in Bothrops jararaca venom gland was characterized by radioligand binding assay and by the ability of isoprenaline to promote accumulation of cyclic AMP in dispersed secretory cells. In both cases, the venom glands were obtained from non-extracted snakes (quiescent stage) or from snakes which venom was extracted 4 days before sacrifice (venom production stimulated stage). [125I]-iodocyanopindolol ([125I]-ICYP) bound to extracted gland membranes in a concentration-dependent and saturable manner, but with low affinity. Propranolol, beta1- or beta2-selective adrenoceptors ligands displaced the [125I]-ICYP binding with low affinity, while selective beta3-adrenoceptor ligands did not displace the [125I]-ICYP binding. The displacement of [125I]-ICYP by propranolol was similar in non-extracted and extracted glands, showing the presence of beta-adrenoceptors in both stages. In dispersed secretory cells of non-extracted glands, isoprenaline (1 microM) increased the cyclic AMP production and propranolol (10 microM) was able to block this effect. On the other hand, in extracted glands, isoprenaline had no effect. The results suggest that the beta-adrenoceptors present in the Bothrops jararaca venom glands are different from those (beta1, beta2 or beta3) described in mammals, but are coupled to the Gs protein, like the known beta-adrenoceptor subtypes. Moreover, previous in vivo stimulation of venom production desensitizes the beta-adrenoceptors system and, although the receptors could be detected by binding studies, they are not coupled to the Gs protein, indicating that beta-adrenoceptors stimulation contributes to the initial steps of venom synthesis.
Asunto(s)
Bothrops/metabolismo , Venenos de Crotálidos/biosíntesis , Receptores Adrenérgicos beta/clasificación , Receptores Adrenérgicos beta/metabolismo , Agonistas de Receptores Adrenérgicos beta 1 , Antagonistas de Receptores Adrenérgicos beta 1 , Agonistas de Receptores Adrenérgicos beta 2 , Antagonistas de Receptores Adrenérgicos beta 2 , Agonistas Adrenérgicos beta/metabolismo , Agonistas Adrenérgicos beta/farmacología , Antagonistas Adrenérgicos beta/metabolismo , Antagonistas Adrenérgicos beta/farmacología , Animales , Unión Competitiva , AMP Cíclico/biosíntesis , Dioxoles/metabolismo , Dioxoles/farmacología , Etanolaminas/metabolismo , Etanolaminas/farmacología , Glándulas Exocrinas/citología , Glándulas Exocrinas/metabolismo , Femenino , Radioisótopos de Yodo , Yodocianopindolol/metabolismo , Yodocianopindolol/farmacología , Isoproterenol/farmacología , Cinética , Masculino , Membranas/metabolismo , Metoprolol/metabolismo , Metoprolol/farmacología , Propanolaminas/metabolismo , Propanolaminas/farmacología , Propranolol/metabolismo , Propranolol/farmacocinética , Ensayo de Unión Radioligante , Receptores Adrenérgicos beta 1/metabolismo , Receptores Adrenérgicos beta 2/metabolismo , Receptores Adrenérgicos beta 3RESUMEN
Objetivo: Evaluar el efecto agudo del metoprolol sobre la función autonómica cardiaca en sujetos seropositivos para T. cruzi asintomáticos. Métodos: Un estudio aleatorizado doble ciego, cruzado, placebo controlado fue realizado en 18 sujetos asintomáticos con serología positiva para T. cruzi. Presión arterial no invasiva y frecuencia cardíaca (FC) fueron registradas continuamente. Las intervenciones al azar fueron: 1 Bolos sucesivos de metoprolol de 5 mg i.v (5 cc) cada 5 minutos, máximo 15 mg (15 cc) buscando disminuir en un 20 por ciento la FC y 2. Bolos sucesivos de solución salina normal (SSN) de 5 cc hasta 3 dosis cada 5 minutos utilizando el mismo criterio. Los marcadores autonómicos calaculados previo y posterior a la intervención: 1. variabilidad de la FC en reposos durante 5 minutos, poder total (TP), poder de baja (LFn) y alta frecuencia (HFn) en unidades normalizadas, ïndice LF/HF y RMSSD. 2. Sensibilidad barorrefleja (BRS) utilizando bolos de fenilefrina (FNF) 150 Mg y nitropusiato (NTP) 100 Mg. El estudio se realizó en dos días consecutivos. Resultados: Los marcadores de la actividad tónica vagal (promedioñSD) antes y después de de la intervención con metoprolol fueron: FC 62.3ñ1.7 vs 55.6ñ1.6 lat/min, LFn 62.8ñ4.4 vs 49.8ñ4.7 ms², LF/HF 2.67ñ0.4 vs 1.42ñ0.2 y RMSSD 26.8ñ3.6 vs 41.9ñ6.4 ms, con valores de p<0.05. Conclusiones: La administración de metoprolol mejoró los marcadores de actividad tónica vagal, sin alterar el tono vagal fásico evaluado por la SBR. Los reflejos cardiovagales pueden ser modificados por la administración aguda de metoprolol en sujetos asintomáticos seropositivos para T. cruzi. Palabras clave: Enfermedad de Chagas, metoprolol, sistema nervioso autónomo, barorreflejo
Asunto(s)
Humanos , Metoprolol/administración & dosificación , Metoprolol/metabolismo , Metoprolol/farmacocinética , Trypanosoma cruzi/citología , Trypanosoma cruzi/aislamiento & purificación , Trypanosoma cruzi/patogenicidad , Trypanosoma cruzi/fisiologíaRESUMEN
1. Repeated swimming stress (three daily sessions) resulted in an increased plasma corticosterone level and subsensitivity of the isolated rat pacemaker to noradrenaline and isoprenaline. 2. Repeated swimming stress was found to decrease the affinity of beta 1-adrenoreceptors for metoprolol. 3. Bilateral adrenalectomy performed 2 days before repeated swimming stress abolished the development of pacemaker subsensitivity to noradrenaline and isoprenaline and the decrease in beta 1-adrenoreceptors affinity for metoprolol. 4. It is concluded that adrenal corticosteroids, at least partially, mediate the swimming stress-induced subsensitivity of the isolated rat pacemaker to noradrenaline and isoprenaline.